Related Experiment Videos
The Association Between Potential Nuclear Factor-Kappa B1 Gene Polymorphism rs28362491 and miR-206 Level in Patients
Isra Muradi1, Jehad Alhmoud1, Moath Al-Qaraleh1
1Medical Laboratory Sciences, Al-Ahliyya Amman University, Al-Salt, Jordan.
World Journal of Oncology
|July 23, 2026
Summary
Reduced miR-206 expression may act as a tumor suppressor in acute lymphoblastic leukemia (ALL). The NF-κB1-94 ATTG polymorphism
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- MicroRNAs (miRNAs) and the nuclear factor-kappa B1 (NF-κB1) pathway are crucial in leukemogenesis.
- The miR-206 and NF-κB1-94 ATTG polymorphism (rs28362491) may influence cancer progression and treatment outcomes.
Purpose of the Study:
- To evaluate miR-206 expression levels in patients with acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma (HL) compared to controls.
- To determine the genotypic distribution of the NF-κB1-94 ATTG polymorphism in these groups.
- To assess the relationship between miR-206 expression, NF-κB1 genotypes, and clinical outcomes in leukemia patients.
Main Methods:
- A retrospective case-control study involving ALL (n=46), HL (n=35), and healthy controls (n=30).
- Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure miR-206 expression.
- PCR and sequencing determined NF-κB1-94 ATTG polymorphism genotypes from tissue and blood samples.
Main Results:
- miR-206 expression was significantly lower in ALL and HL patients compared to healthy controls, suggesting a tumor suppressor role.
- The homozygous Ins/Ins genotype of NF-κB1 (rs28362491) was more prevalent in ALL patients than controls.
- No significant correlation was found between miR-206 levels and NF-κB1 genotypes or remission status.
Conclusions:
- No significant difference in miR-206 expression was observed across different NF-κB1-94 ATTG genotypes.
- Reduced miR-206 expression may function as a tumor suppressor in ALL.
- The NF-κB1 polymorphism did not significantly affect remission status in ALL patients, but both factors may serve as potential biomarkers.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...